Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/ Medivation AD drug fails trial

Pfizer and Medivation's Alzheimer's Disease treatment, Dimebon (latrepirdin), has failed to meet its efficacy endpoints in a phase III trial

Pfizer and Medivation's Alzheimer's Disease (AD) treatment, Dimebon (latrepirdin), has failed to meet its co-primary or secondary efficacy endpoints in a phase III trial.

The phase III, multi-national, double-blind, placebo-controlled ,CONNECTION trial, involved 598 patients with mild-to-moderate AD.

Dr David Hung, president and CEO of Medivation, said: "The results from the CONNECTION study are unexpected, and we are disappointed for the Alzheimer's community." 

He went on to say that Medivation would be working with Pfizer to analyse the data from the trial. 

Dr Briggs W Morrison, senior vice president, clinical development, Primary Care Business Unit at Pfizer said: "We recognise the significant medical need, and we are committed to advancing treatment options for Alzheimer's disease."

Both the CONNECTION study and a separate phase III study found Dimebon to be well tolerated when dosed alone or in combination with other approved AD therapies.

Dimebon is being studied in four other ongoing randomised, double-blind, placebo-controlled phase III studies, which currently are enrolling. 

Medivation and Pfizer have a global collaboration to develop and commercialise Dimebon for the treatment of Alzheimer's disease and Huntington's disease. Under the terms of the agreement, the companies work together on the Dimebon development programme.

4th March 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics